Evotec sues Andromeda after DiaPep277 deception

Germany's Evotec has taken legal steps against Israel's Andromeda Biotech in an effort to recoup its losses following Andromeda's falsification of trial results for diabetes drug DiaPep277. Evotec's stock took a dive when the deception came to light earlier in September and has yet to recover.

Germany's Evotec has taken legal steps against Israel's Andromeda Biotech in an effort to recoup its losses following Andromeda's falsification of trial results for diabetes drug DiaPep277. Evotec's stock took a dive when the deception came to light earlier in September and has yet to recover.

Andromeda was developing DiaPep277 as a treatment for type 1 diabetes, and data from the program was what attracted Hyperion...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

More from Therapy Areas